Howard Kynaston
A5076170377- Prostate Cancer Treatment and Research
- Prostate Cancer Diagnosis and Treatment
- Bladder and Urothelial Cancer Treatments
- Urinary and Genital Oncology Studies
- Urological Disorders and Treatments
- Hormonal and reproductive studies
- Cell Adhesion Molecules Research
- Inflammatory mediators and NSAID effects
- Advanced Radiotherapy Techniques
- TGF-β signaling in diseases
- Statistical Methods in Clinical Trials
- Urinary Bladder and Prostate Research
- Estrogen and related hormone effects
- Urologic and reproductive health conditions
- Cancer, Lipids, and Metabolism
- Health Systems, Economic Evaluations, Quality of Life
- Bone health and treatments
- Connective Tissue Growth Factor Research
- Radiopharmaceutical Chemistry and Applications
- Renal cell carcinoma treatment
- Infectious Disease Case Reports and Treatments
- Cellular Mechanics and Interactions
- Blood properties and coagulation
- Colorectal Cancer Screening and Detection
- Pelvic floor disorders treatments
University Hospital of Wales
2014-2024
Cardiff University
2015-2024
Cardiff and Vale University Health Board
2013-2024
Men's Health Boston
2018
Faculty of Media
2016
Bio-Medical Science (South Korea)
2016
Radiation Oncology Associates
2016
Clarke (United States)
2016
Medical Research Council
2011
Mid Yorkshire Hospitals NHS Trust
2011
The comparative effectiveness of treatments for prostate cancer that is detected by prostate-specific antigen (PSA) testing remains uncertain.
Robust data on patient-reported outcome measures comparing treatments for clinically localized prostate cancer are lacking. We investigated the effects of active monitoring, radical prostatectomy, and radiotherapy with hormones outcomes.
Sex hormones appear to play a pivotal role in determining cardiovascular risk. Androgen deprivation therapy for males with prostate cancer results hypogonadal state that may have important, but as yet undetermined, effects on the vasculature. We studied of androgen large artery stiffness 22 patients (mean age, 67 +/- 8 yr) over 6-month period. Arterial was assessed using pulse-wave analysis, technique measures peripheral arterial pressure waveforms and generates corresponding central aortic...
Between 1999 and 2009 in the United Kingdom, 82,429 men between 50 69 years of age received a prostate-specific antigen (PSA) test. Localized prostate cancer was diagnosed 2664 men. Of these men, 1643 were enrolled trial to evaluate effectiveness treatments, with 545 randomly assigned receive active monitoring, 553 undergo prostatectomy, radiotherapy.
BackgroundLong-term patient-reported outcomes are needed to inform treatment decisions for localized prostate cancer.MethodsPatient-reported of 1643 randomly assigned participants in the ProtecT (Prostate Testing Cancer and Treatment) trial were evaluated assess functional quality-of-life impacts prostatectomy, radiotherapy with neoadjuvant androgen deprivation, active monitoring. This article focuses on from 7 12 years using mixed effects linear logistic models.ResultsResponse rates...
Previous evidence indicates that adjuvant, short-course androgen deprivation therapy (ADT) improves metastasis-free survival when given with primary radiotherapy for intermediate-risk and high-risk localised prostate cancer. However, the value of ADT postoperative after radical prostatectomy is unclear.
The optimal timing of radiotherapy (RT) after radical prostatectomy for prostate cancer has been uncertain. RADICALS-RT compared efficacy and safety adjuvant RT versus an observation policy with salvage prostate-specific antigen (PSA) failure.
There is a considerable body of pre-clinical, epidemiological and randomised data to support the hypothesis that aspirin has potential be an effective adjuvant cancer therapy.
The ProtecT trial reported intention-to-treat analysis of men with localised prostate cancer (PCa) randomly allocated to active monitoring (AM), radical prostatectomy, and external beam radiotherapy. To determine report outcomes according treatment received in randomised choice cohorts. This study focuses on secondary care. Men clinically at one nine UK centres were invited participate the comparing AM, Two cohorts included 1643 who agreed be randomised; 997 declined randomisation chose...
To investigate the functional and quality of life (QoL) outcomes treatments for localised prostate cancer inform treatment decision-making.Men aged 50-69 years diagnosed with by prostate-specific antigen testing biopsies at nine UK centres in Prostate Testing Cancer Treatment (ProtecT) trial were randomised to, or chose one of, three treatments. Of 2565 participants, 1135 men received active monitoring (AM), 750 a radical prostatectomy (RP), 603 external-beam radiotherapy (EBRT) concurrent...
There is growing interest in the vitro generation of dendritic cells (DC) from peripheral blood monocytes, but effect method chosen to isolate CD14+ monocytes for subsequent DC poorly documented. The used may have an impact on function by affecting their ability express costimulatory molecules (CD80/86), maturation marker (CD83) and/or produce important immunomodulatory cytokines. In this study, we show that positive selection anti-CD14-coated microbeads inhibits lipopolysaccharide...
To determine the level of psychopathology, traumatic distress and quality life in men with newly diagnosed clinically localized prostate cancer, effect on these a consultation combined-specialist early-prostate clinic, predictors psychopathology.Eighty-eight patients were recruited from combined clinic; they completed battery questionnaires including Hospital Anxiety Depression Scale (HADS), revised Impact Event (IES) European Organization for Research Treatment Cancer Quality Life...
Luteinising-hormone-releasing-hormone agonists (LHRHa) to treat prostate cancer are associated with long-term toxic effects, including osteoporosis. Use of parenteral oestrogen could avoid the complications LHRHa and thromboembolic oral oestrogen.In this multicentre, open-label, randomised, phase 2 trial, we enrolled men locally advanced or metastatic scheduled start indefinite hormone therapy. Randomisation was by minimisation, in a 2:1 ratio, four self-administered patches (100 μg per 24...